NCT06929624Active, not recruitingPhase 3
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 282 (actual)
- First submitted
- 8 Apr 2025
- Start date
- 24 Apr 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06929624
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 282
- From 24 Apr 2025 to the primary completion date, Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have only one prior line therapy and are candidates for stem cell transplantation.
Other illness
- A history of immunodeficiency.
- A history of severe cardiovascular disease.
- A history of other malignancies within 5 years prior to administration of the first dose.
Other
- Central nervous system lymphoma involvement.
- Primary mediastinal (thymus) large B-cell lymphoma.
Who the study is looking for
- Histologically confirmed diffuse large B-cell lymphoma (DLBCL).
- Have received ≥1 line of systemic antitumor therapy.
- At least one bi-dimensionally measurable lesion.
- Expected survival of at least 3 months.
- Age ≥18 years old and under 80 years old.
- The patients voluntarily participated in the study, signed informed consent, had good compliance and were willing to cooperate with follow-up.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.